Barclays launches Biomarin Pharmaceutical Inc. (BMRN) with purchase ratings

Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) in Best genomics stock to buy according to hedge funds. Barclays’ Gena Wang maintained Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) in a purchase rating in a report published June 10th with a price target of $86.00.

A pharmaceutical plant that produces the unique synthetic oral form of C-type natriuretic peptides.

According to the latest revenue report from Biomarin Pharmaceutical Inc. (NASDAQ: BMRN), the company had revenue of $745.15 million for the quarter ended March 31, with net profit of $185.69 million.

As Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) builds a portfolio of genetic disease therapy, it is difficult to avoid past comparisons with Genzyme (purchased by Sanofi). Despite having several permitted treatments, the company has spent years on commercialization and R&D costs, but analysts are optimistic about the long-term and profitable potential of its current portfolio. It is in a strong position due to its ability to add expansion through large internal pipelines and strategic acquisition.

Although we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater potential for a rise and pose a risk of a decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: 10 High-Growth EV Stocks to Invest and 13 best car stocks to buy in 2025.

Disclosure. none.